New concepts for treatment of non-insulin-dependent diabetes mellitus

Trends in Endocrinology and Metabolism

Volumn 8, Issue 5, 1997, Pages 187-191

  Larkins, Richard G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; INSULIN; SULFONYLUREA; TROGLITAZONE;

COMORBIDITY; CORONARY RISK; DIABETIC DIET; GLUCOSE UTILIZATION; HUMAN; INSULIN RELEASE; KINESIOTHERAPY; MATERNAL DIABETES MELLITUS; NEWBORN MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREMATURITY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0030860790     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(97)00037-4     Document Type: Article

References (45)

1. American Diabetes Association. Clinical Practice Recommendations: 1993. Detection and management of lipid disorders in diabetes [consensus statement]. Diabet Care 16(Suppl 2):106-112.
2. Ashcroft FM: 1996. Mechanisms of the glycemic effects of sulfonylureas. Horm Metab Res 28:456-463.
3. Bailey CJ, Turner RC: 1996. Metformin. N Engl J Med 334:574-579.
4. Best JD, Jerums G, Newnham HH, O'Brien RC: 1995. Diabetic dyslipidaemia: Australian Diabetes Society position statement. Med J Aust 162:91-93.
5. Chaiken RL, Eckert-Norton M, Pasmantier R, et al.: 1995. Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia 38:1307-1312.
6. Cigolini M, Bosello O, Zancanoro C, Orlandi PG, Fezzi O, Smith U: 1984. Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabete Metab 10:311-315.
7. De Fronzo RA: 1992. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35:389-397.
8. De Fronzo RA, Barzilai N, Simonson DC: 1991. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 73:1294-1301.
9. Escobarjiminez F, Barajas C, Deleiva A, et al.: 1995. Efficacy and tolerability of miglitol in the treatment of patients with non-insulin-dependent diabetes mellitus. Curr Ther Res Clin Exp 56:258-268.
10. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812.
11. Galuska D, Nolte LA, Zierath JR, Wallberg-Henricksson H: 1994. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 37:826-832.
12. Gerich JE: 1989. Oral hypoglycemic agents. N Engl J Med 321:1231-1245.
13. Hales CN, Barker DJP: 1992. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35:595-601.
14. Hotamisligil GS, Shargill NS, Spiegelman BM: 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87-91.
15. Jarrett RJ: 1984. The epidemiology of coronary heart disease and related factors in the context of diabetes mellitus and impaired glucose tolerance. In Jarrett RJ, ed. Diabetes and Heart Disease. Amsterdam, Elsevier Sciences BV, pp 1-23.
16. Kannel WB, McGee DL: 1979. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the framingham study. Diabetes Care 2:120-126.
17. Kumar S, Boulton AJM, Beck-Nielsen H, et al. for the Troglitazone Study Group: 1996. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. 39:701-709.
18. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J Biol Chem 270:12,953-12,956.
19. Lillioja S, Mott DM, Spraul M, et al.: 1993. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 329:1988-1992.
20. Loubatières A: 1957. The mechanism of action of the hypoglycemic sulfonamides: a concept based on investigations in animals and in men. Ann NY Acad Sci 7:192-196.
21. Matthaei S, Hamann A, Klein HH, et al.: 1991. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 40:850-857.
22. Melander A, Bitzén P-O, Faber O, Groop L: 1989. Sulfonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 37:58-72.
23. Microalbuminuria Captopril Study Group: 1996. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39:587-593.
24. Mogensen C: 1984. Microalbuminuria predicts clinical proteinuria and increased mortality. N Engl J Med 310:356-360.
25. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treatment with troglitazone. N Engl J Med 331:1188-1193.
26. Nutrition and Diabetes Study Group of the European Association for the Study of Diabetes: 1988. Nutritional recommendations and principles for individuals with diabetes mellitus. Diabet Nutr Metab 1:145-149.
27. O'Dea K: 1984. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian Aborigines after temporary reversion to traditional lifestyle. Diabetes 33:596-603.
28. Pyörälä K, Laakso M, Uusitupa M: 1987. Diabetes and atherosclerosis: an epidemiologic view. Diabet Metab Rev 3:464-524.
29. Quatraro A, Giugliano D: 1993. The combination of insulin and oral hypoglycemic drugs: a continuous challenge. Diabet Metab 19: 219-224.
30. Rasmussen O, Lauszus FF, Christiansen C, Thomsen C, Hermansen K: 1996. Differential effects of saturated and monounsaturated fat on blood glucose and insulin responses in subjects with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 63:249-253.
31. Reaven GM, Chen YDI: 1996. Insulin resistance, its consequences, and coronary heart disease: must we choose one culprit. Circulation 93:1780-1783.
32. Reitman JS, Vasquez B, Klimes I, Nagulesparan M: 1986. Improvement of glucose homeostasis after exercise training in non-insulin-dependent diabetes. Diabetes Care 7:434-441.
33. Saltiel AR, Olefsky JM: 1996. Thiazglidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669.
34. Shah M, Garg A: 1996. High-fat and high-carbohydrate diets and energy balance. Diabetes Care 19:1142-1153.
35. Soneru IL, Agrawal L, Murphy JC, Lawrence AM, Abraira C: 1993. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care 16:896-901.
36. Suter SL, Nolan JJ, Wallace P, et al.: 1992. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203.
37. Taskinen MR, Lahdenpera S, Syvanne M: 1996. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 28:335-340.
38. UK Prospective Diabetes Study Group: 1991. UK prospective diabetes study (UK PDS) VIII: study design, progress and performance. Diabetologia 34:877-890.
39. UK Prospective Diabetes Study Group: 1995. UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258.
40. University Group Diabetes Program: 1970. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes 2: mortality results. Diabetes 19(Suppl 2):785-830.
41. Westermark P, Johnson KH, O'Brien TD, Betsholtz C: 1992. Islet amyloid polypeptide: a novel controversy in diabetes research. Diabetologia 35:297-303.
42. Yee HS, Fong NT: 1996. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy 16:792-805.
43. Yki-Järvinen H: 1994. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343:91-95.
44. Yki-Järvinen H, Kauppila M, Kujansuu E, et al.: 1992. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433.
45. Young PW, Cawthorne MA, Coyle PJ, et al.: 1995. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44:1087-1092.